Overview

Study of NAC of GA Therapy for Patients With BRPC

Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy on survival time as a preoperative chemotherapy, the investigators use the NAC-GA regimen includes only two cycles (three times weekly and one week rest) of GA regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Wakayama Medical University
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel